Immune modulating medication
A Janus kinase inhibitor , also known as JAK inhibitor or jakinib ,[1] is a type of immune modulating medication, which inhibits the activity of one or more of the Janus kinase family of enzymes (JAK1 , JAK2 , JAK3 , TYK2 ), thereby interfering with the JAK-STAT signaling pathway in lymphocytes.
It is used in the treatment of cancer and inflammatory diseases [1] [2] such as rheumatoid arthritis [3] and various skin conditions.[4] A Janus kinase 3 inhibitor is attractive as a possible treatment of various autoimmune diseases since its function is mainly restricted to lymphocytes . As of 2017, development of a selective JAK3 inhibitor was ongoing.[5]
^ a b Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ (August 2012). "Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease" . Current Opinion in Pharmacology . 12 (4): 464–70. doi :10.1016/j.coph.2012.06.008 . PMC 3419278 . PMID 22819198 .
^ Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ (June 2008). "Therapeutic targeting of Janus kinases" . Immunological Reviews . 223 : 132–42. doi :10.1111/j.1600-065X.2008.00644.x . PMC 2634846 . PMID 18613833 .
^ Norman P (August 2014). "Selective JAK inhibitors in development for rheumatoid arthritis". Expert Opinion on Investigational Drugs . 23 (8): 1067–77. doi :10.1517/13543784.2014.918604 . PMID 24818516 . S2CID 21143324 .
^ "JAK Inhibitors Showing Promise for Many Skin Problems - Conditions ranging from alopecia to vitiligo" . 6 July 2017. Archived from the original on 13 July 2017. Retrieved 9 July 2017 .
^ Forster M, Gehringer M, Laufer SA (September 2017). "Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting". Bioorganic & Medicinal Chemistry Letters . 27 (18): 4229–4237. doi :10.1016/j.bmcl.2017.07.079 . PMID 28844493 .